Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
11.06.2024 - Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, ...
United States International Number Toll Exchange Commission B Development Women Health Indications Company Phase
Source: wallstreet-online.de